Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Bristol-Myers Squibb (NY: BMY)
60.79 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 7:17 AM EDT, May 26, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 299
Open 60.79
Bid (Size) 61.51 (5)
Ask (Size) 61.75 (2)
Prev. Close 60.79
Today's Range 60.79 - 60.79
52wk Range 42.48 - 68.34
Shares Outstanding 1,634,538,458
Dividend Yield 2.63%
Performance
YTD
-4.03%
-4.03%
1 Month
-0.23%
-0.23%
3 Month
-7.37%
-7.37%
6 Month
+7.69%
+7.69%
1 Year
+28.52%
+28.52%
Top News
More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT
from GlobeNewswire News Releases
European Medicines Agency Validates Bristol Myers Squibb’s Applications for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486
European Medicines Agency Validates Bristol Myers Squibb’s Applications for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486 Read More
from Business Wire News Releases
More News
Read More
Bristol Myers Squibb Research at EHA 2020 Demonstrates Continued Advances Across Multiple Blood Diseases
from Business Wire News Releases
Bristol-Myers - A Strong Buy For Growth Income
category Pharma/Biotech , Healthcare , Stocks / Equities
from Blogs - TalkMarkets
Noteworthy ETF Inflows: MTUM, BMY, ABBV, VRTX
category ETFs
from ETF Channel
Teladoc, Bristol Myers, Quidel, Neurocrine Bio, Tandem Diabetes: 5 Health Stocks To Monitor Closely
from Investor's Business Daily
FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”
category Market News , BLUE , BMY , and 1 more.
from Motley Fool
CORRECTED-UPDATE 1-Roche's Tecentriq wins FDA approval as first-line therapy for some lung cancer forms (May 18)
category companyNews
from Reuters: Company News
Checkpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment Market
category Benzinga , MRK , CKPT , and 17 more.
from Benzinga
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
category ABBV , NTLA , REGN , and 5 more.
from Motley Fool
Telemedicine A COVID-19 Winner
category Markets , AMGN , BMY , and 10 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.